A randomized, open-label, single-dose, two-way crossover study to assess the pharmacokinetics between two tablets of fixed-dose combination formulation with raloxifene and cholecalciferol and concomitant administration of each agents in healthy male volunteers

A new fixed-dose combination (FDC) formulation of raloxifene 60 mg and cholecalciferol 800 IU was developed to improve the medication compliance and overall efficacy of raloxifene treatment in postmenopausal osteoporosis patients. The aim of this study was to compare the pharmacokinetics between two...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hae Won, Kang, Woo Youl, Gwon, Mi-Ri, Choi, Eun Jung, Kim, Eun Hee, Cho, Kyunghee, Lee, Bakhwan, Seong, Sook Jin, Yoon, Young-Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Clinical Pharmacology and Therapeutics 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532856/
https://www.ncbi.nlm.nih.gov/pubmed/36247744
http://dx.doi.org/10.12793/tcp.2022.30.e13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532856/
https://www.ncbi.nlm.nih.gov/pubmed/36247744
http://dx.doi.org/10.12793/tcp.2022.30.e13

Ejemplares similares